NasdaqGS:SNNA

Stock Analysis Report

Executive Summary

Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas.

Snowflake

Fundamentals

Overvalued with worrying balance sheet.

Share Price & News

How has Sienna Biopharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-18.1%

SNNA

-0.06%

US Pharmaceuticals

0.4%

US Market


1 Year Return

-98.2%

SNNA

-8.0%

US Pharmaceuticals

6.9%

US Market

Return vs Industry: SNNA underperformed the US Pharmaceuticals industry which returned -8% over the past year.

Return vs Market: SNNA underperformed the US Market which returned 6.9% over the past year.


Shareholder returns

SNNAIndustryMarket
7 Day-18.1%-0.06%0.4%
30 Day28.4%-0.9%-1.1%
90 Day-73.6%-1.7%-0.5%
1 Year-98.2%-98.2%-5.8%-8.0%9.3%6.9%
3 Yearn/a18.3%10.0%45.8%36.4%
5 Yearn/a22.1%9.2%62.9%45.1%

Price Volatility Vs. Market

How volatile is Sienna Biopharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sienna Biopharmaceuticals undervalued compared to its fair value and its price relative to the market?

0.23x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate SNNA's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate SNNA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SNNA is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: SNNA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate SNNA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SNNA is good value based on its PB Ratio (0.2x) compared to the US Pharmaceuticals industry average (2.9x).


Next Steps

Future Growth

How is Sienna Biopharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

14.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sienna Biopharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Sienna Biopharmaceuticals performed over the past 5 years?

-39.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: SNNA is unprofitable, and losses have increased over the past 5 years at a rate of -39.1% per year.

Accelerating Growth: Unable to compare SNNA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SNNA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (24.3%).


Return on Equity

High ROE: SNNA has a negative Return on Equity (-225.23%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: SNNA is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: SNNA is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Sienna Biopharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: SNNA's short term assets ($50.6M) exceeds its short term liabilities ($20.8M)

Long Term Liabilities: SNNA's short term assets (50.6M) do not cover its long term liabilities (59.8M)


Debt to Equity History and Analysis

Debt Level: SNNA's debt to equity ratio (109.2%) is considered high

Reducing Debt: Insufficient data to determine if SNNA's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: SNNA has a low level of unsold assets or inventory.

Debt Coverage by Assets: SNNA's debt is covered by short term assets (assets are 1.717340x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SNNA has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: SNNA has less than a year of cash runway if free cash flow continues to reduce at historical rates of -41.7% each year


Next Steps

Dividend

What is Sienna Biopharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate SNNA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SNNA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if SNNA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SNNA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SNNA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Sienna Biopharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

2.6yrs

Average management tenure


CEO

Frederick Beddingfield (54yo)

3.8yrs

Tenure

US$2,616,799

Compensation

Dr. Frederick C. Beddingfield, III, M.D., Ph.D. has been the Chief Executive Officer and President of Sienna Labs, Inc. since January 2016. Dr. Beddingfield has been the Chief Medical Officer of Kythera Bi ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Frederick's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Frederick's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.6yrs

Average Tenure

49yo

Average Age

Experienced Management: SNNA's management team is considered experienced (2.6 years average tenure).


Board Age and Tenure

3.4yrs

Average Tenure

55.5yo

Average Age

Experienced Board: SNNA's board of directors are considered experienced (3.4 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$5,414,50027 Feb 19
Arch Venture Partners, L.P.
EntityCompany
Shares2,165,800
Max PriceUS$2.50
BuyUS$250,00026 Feb 19
Robert More
EntityIndividual
Role
Member of the Board of Directors
Director
Shares100,000
Max PriceUS$2.50
BuyUS$250,00026 Feb 19
Keith Leonard
EntityIndividual
Role
Chairman of the Board
Chairman
Shares100,000
Max PriceUS$2.50
BuyUS$100,00026 Feb 19
Frederick Beddingfield
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares40,000
Max PriceUS$2.50

Ownership Breakdown


Management Team

  • David E. Pyott (66yo)

    Strategic Advisor to the Board and CEO

    • Tenure: 2.3yrs
  • Ted Schwartz (58yo)

    Head of Global Strategic Marketing

    • Tenure: 3.8yrs
  • Silvio Traversa (49yo)

    Chief Scientific Officer

    • Tenure: 2.8yrs
  • Timothy Andrews (40yo)

    General Counsel & Corporate Secretary

    • Tenure: 3yrs
    • Compensation: US$1.03m
  • Frederick Beddingfield (54yo)

    CEO, President & Director

    • Tenure: 3.8yrs
    • Compensation: US$2.62m
  • Paul Lizzul (44yo)

    Chief Medical Officer

    • Tenure: 3.8yrs
    • Compensation: US$400.76k
  • Sean Andrews

    Vice President of Investor Relations

    • Tenure: 2.4yrs
  • Caroline Van Hove

    Chief Commercial Officer

    • Tenure: 1.6yrs
  • Michael Attar

    VP & Head of Corporate Development

    • Tenure: 0.9yrs
  • Alex Azoy (43yo)

    CFO & Controller

    • Tenure: 0.5yrs

Board Members

  • Bob More (51yo)

    Director

    • Tenure: 6.4yrs
    • Compensation: US$139.22k
  • Jim Hindman (58yo)

    Director

    • Tenure: 1.2yrs
    • Compensation: US$212.72k
  • Dennis Fenton (67yo)

    Director

    • Tenure: 3yrs
    • Compensation: US$147.97k
  • Diane Berson (60yo)

    Member of Corporate Advisory Board

    • Tenure: 1.8yrs
  • Robert Bissonnette

    Member of Corporate Advisory Board

    • Tenure: 1.8yrs
  • Keith Leonard (57yo)

    Chairman

    • Tenure: 3.8yrs
    • Compensation: US$171.72k
  • Kristina Burow (46yo)

    Director

    • Tenure: 4yrs
    • Compensation: US$137.97k
  • Frederick Beddingfield (54yo)

    CEO, President & Director

    • Tenure: 3.8yrs
    • Compensation: US$2.62m
  • Matthew Avram

    Member of Corporate Advisory Board

    • Tenure: 1.8yrs
  • Todd Harris (40yo)

    Director

    • Tenure: 9.8yrs
    • Compensation: US$264.51k

Company Information

Sienna Biopharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sienna Biopharmaceuticals, Inc.
  • Ticker: SNNA
  • Exchange: NasdaqGS
  • Founded: 2010
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$6.289m
  • Shares outstanding: 30.71m
  • Website: https://www.siennabio.com

Number of Employees


Location

  • Sienna Biopharmaceuticals, Inc.
  • 30699 Russell Ranch Road
  • Suite 140
  • Westlake Village
  • California
  • 91362
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SNNANasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJul 2017
1ARDB (Deutsche Boerse AG)YesCommon StockDEEURJul 2017

Biography

Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that targ ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/20 00:49
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.